Vysis® UroVysion for the detection of urothelial carcinoma

被引：78
|
作者：
Halling, KC [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Lab Genet, Rochester, MN 55905 USA
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2003年 / 3卷 / 04期
基金：
美国国家科学基金会;
关键词：
bladder cancer; bladder tumor markers; FISH; urine cytology; urothelial carcinoma; Vysis (R) UroVysion;
D O I：
10.1586/14737159.3.4.507
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
For decades, cystoscopy and urine cytology have been the mainstay for monitoring superficial urothelial carcinoma patients for tumor recurrence. However, urine cytology has poor sensitivity for urothelial carcinoma and, consequently, numerous investigators have been endeavoring to develop more sensitive assays for the detection of urothelial carcinoma. This article presents an overview of the types of new assays that have been developed for urothelial carcinoma detection but focuses primarily on the features and performance of a new fluorescence in situ hybridization assay for urothelial carcinoma detection known as Vysis(R) UroVysion.
引用
收藏
页码：507 / 519
页数：13
相关论文
共 50 条
  • [41] Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study
    Guo, Run-Qi
    Xiong, Geng-Yan
    Yang, Kai-Wei
    Zhang, Lei
    He, Shi-Ming
    Gong, Yan-Qing
    He, Qun
    Li, Xue-Ying
    Wang, Zi-Cheng
    Bao, Zhen-Qing
    Li, Xue-Song
    Zhang, Kai
    Zhou, Li-Qun
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (07) : 342.e15 - 342.e23
  • [42] Quantitative Loss of Heterozygosity Analysis for Urothelial Carcinoma Detection and Prognosis
    Collin-Chavagnac, Delphine
    Marcais, Christophe
    Billon, Stephane
    Descotes, Francoise
    Piaton, Eric
    Decaussin, Myriam
    Rodriguez-Lafrasse, Claire
    Ruffion, Alain
    UROLOGY, 2010, 76 (02) : 515.e1 - 515.e7
  • [43] Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
    Iwamura, Hiromichi
    Hatakeyama, Shingo
    Sato, Makoto
    Ohyama, Chikara
    MEDICAL ONCOLOGY, 2018, 35 (06)
  • [44] Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
    Hiromichi Iwamura
    Shingo Hatakeyama
    Makoto Sato
    Chikara Ohyama
    Medical Oncology, 2018, 35
  • [45] Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications
    Wu, Siyu
    Li, Rong
    Jiang, Yuanhong
    Yu, Jiazheng
    Zheng, Jianyi
    Li, Zeyu
    Li, Mingyang
    Xin, Kerong
    Wang, Yang
    Xu, Zhenqun
    Li, Shijie
    Chen, Xiaonan
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 165
  • [46] Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma
    Tripathi, Nishita
    Jo, Yeonjung
    Tripathi, Abhishek
    Sayegh, Nicolas
    Li, Haoran
    Nussenzveig, Roberto
    Haaland, Benjamin
    Thomas, Vinay M.
    Gupta, Sumati
    Maughan, Benjamin L.
    Swami, Umang
    Pal, Sumanta K.
    Grivas, Petros
    Agarwal, Neeraj
    Sirohi, Deepika
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (11) : 493.e1 - 493.e7
  • [47] Urothelial carcinoma
    Merseburger, Axel S.
    Shariat, Shahrokh F.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (04) : 405 - 407
  • [48] Angiogenesis as a therapeutic target in urothelial carcinoma
    Pinto, Alvaro
    Redondo, Andres
    Zamora, Pilar
    Castelo, Beatriz
    Espinosa, Enrique
    ANTI-CANCER DRUGS, 2010, 21 (10) : 890 - 896
  • [49] Urothelial carcinoma: Recurrence and risk factors
    Milojevic, Bogomir
    Dzarnic, Zoran
    Kajmakovic, Boris
    Petronic, Dragica Milenkovic
    Grujicic, Sandra Sipetic
    JOURNAL OF BUON, 2015, 20 (02): : 391 - 398
  • [50] Systemic treatments for metastatic urothelial carcinoma
    Lalani, Aly-Khan A.
    Sonpavde, Guru P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 201 - 208
12345